Justin Walsh
Stock Analyst at Jones Trading
(3.00)
# 1,371
Out of 5,090 analysts
37
Total ratings
40%
Success rate
14.22%
Average return
Main Sectors:
Stocks Rated by Justin Walsh
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PRAX Praxis Precision Medicines | Initiates: Buy | $83 | $247.99 | -66.53% | 1 | Sep 18, 2025 | |
| LNTH Lantheus Holdings | Maintains: Buy | $109 → $84 | $63.30 | +32.70% | 10 | Sep 16, 2025 | |
| VNRX VolitionRx | Initiates: Buy | $3 | $0.30 | +901.00% | 1 | Jun 10, 2025 | |
| BLRX BioLineRx | Upgrades: Buy | $12 | $3.38 | +255.03% | 3 | May 30, 2025 | |
| CLNN Clene | Initiates: Buy | $30 | $5.77 | +419.93% | 1 | Apr 23, 2025 | |
| MNPR Monopar Therapeutics | Downgrades: Hold | n/a | $80.38 | - | 1 | Apr 2, 2025 | |
| SER Serina Therapeutics | Initiates: Buy | $11 | $3.25 | +238.46% | 1 | Mar 11, 2025 | |
| ANRO Alto Neuroscience | Initiates: Buy | $18 | $13.43 | +34.03% | 1 | Dec 16, 2024 | |
| RAPP Rapport Therapeutics | Initiates: Buy | $42 | $29.50 | +42.37% | 1 | Oct 18, 2024 | |
| CATX Perspective Therapeutics | Maintains: Buy | $15 → $22 | $2.40 | +816.67% | 2 | May 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $16 | $7.06 | +126.63% | 1 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $4.62 | +332.90% | 1 | Apr 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $4 | $0.73 | +447.87% | 4 | Sep 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $3.74 | +434.76% | 1 | Sep 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $360 | $8.18 | +4,300.98% | 2 | May 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $440 | $1.16 | +37,831.03% | 1 | Feb 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $75 | $0.65 | +11,438.46% | 1 | Oct 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $17 → $20 | $45.75 | -56.28% | 1 | May 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $440 → $200 | $1.35 | +14,714.81% | 2 | Apr 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $5.53 | +80.83% | 1 | Jan 19, 2022 |
Praxis Precision Medicines
Sep 18, 2025
Initiates: Buy
Price Target: $83
Current: $247.99
Upside: -66.53%
Lantheus Holdings
Sep 16, 2025
Maintains: Buy
Price Target: $109 → $84
Current: $63.30
Upside: +32.70%
VolitionRx
Jun 10, 2025
Initiates: Buy
Price Target: $3
Current: $0.30
Upside: +901.00%
BioLineRx
May 30, 2025
Upgrades: Buy
Price Target: $12
Current: $3.38
Upside: +255.03%
Clene
Apr 23, 2025
Initiates: Buy
Price Target: $30
Current: $5.77
Upside: +419.93%
Monopar Therapeutics
Apr 2, 2025
Downgrades: Hold
Price Target: n/a
Current: $80.38
Upside: -
Serina Therapeutics
Mar 11, 2025
Initiates: Buy
Price Target: $11
Current: $3.25
Upside: +238.46%
Alto Neuroscience
Dec 16, 2024
Initiates: Buy
Price Target: $18
Current: $13.43
Upside: +34.03%
Rapport Therapeutics
Oct 18, 2024
Initiates: Buy
Price Target: $42
Current: $29.50
Upside: +42.37%
Perspective Therapeutics
May 16, 2024
Maintains: Buy
Price Target: $15 → $22
Current: $2.40
Upside: +816.67%
May 10, 2024
Initiates: Buy
Price Target: $16
Current: $7.06
Upside: +126.63%
Apr 17, 2024
Initiates: Buy
Price Target: $20
Current: $4.62
Upside: +332.90%
Sep 7, 2023
Reinstates: Buy
Price Target: $4
Current: $0.73
Upside: +447.87%
Sep 6, 2023
Initiates: Buy
Price Target: $20
Current: $3.74
Upside: +434.76%
May 16, 2023
Initiates: Buy
Price Target: $360
Current: $8.18
Upside: +4,300.98%
Feb 10, 2023
Initiates: Buy
Price Target: $440
Current: $1.16
Upside: +37,831.03%
Oct 7, 2022
Initiates: Buy
Price Target: $75
Current: $0.65
Upside: +11,438.46%
May 20, 2022
Maintains: Buy
Price Target: $17 → $20
Current: $45.75
Upside: -56.28%
Apr 5, 2022
Maintains: Buy
Price Target: $440 → $200
Current: $1.35
Upside: +14,714.81%
Jan 19, 2022
Initiates: Buy
Price Target: $10
Current: $5.53
Upside: +80.83%